The earnings call highlighted significant growth in FILSPARI sales and expansion approvals in Europe and the UK. The anticipation of approval for a new indication in FSGS is promising. However, financial challenges such as higher gross to net discounts and anticipated generic competition for Thiola present concerns. Despite the net loss, the company's financial performance showed improvement over the previous year.

Company Guidance -

Q3 2025

During the Travere Therapeutics Q1 2025 earnings call, the company provided several key metrics showcasing strong performance and strategic progress. FILSPARI's net sales grew by 182% year-over-year and 13% quarter-over-quarter, reaching approximately $56 million in Q1 2025. Travere received 703 new patient start forms in the quarter, indicating robust demand. The company anticipates potential FDA approval for FILSPARI in FSGS by September, which could open a market of up to 30,000 addressable patients. Additionally, Travere reported total revenues of $81.7 million for the quarter, with a net loss of $41.2 million, or $0.47 per share. The company ended Q1 with $322.2 million in cash and marketable securities, bolstered by expected milestone payments from partners. Travere also highlighted the upcoming PDUFA date of August 28 for a submission to modify FILSPARI's REMS program, which could further enhance product convenience and patient access.

FILSPARI Sales and Growth

Net sales for FILSPARI grew 182% year-over-year and 13% versus the prior quarter, reflecting strong demand and uptake. The drug achieved $56 million in net product sales in the first quarter.

European and UK Approval for FILSPARI

The European Commission and MHRA in the UK converted FILSPARI's conditional approvals to full approvals for the treatment of adults with IgA nephropathy.

sNDA Submission for FSGS

The company completed its submission for an sNDA for FILSPARI for the FSGS indication in March, expecting potential approval as early as September, marking a historic milestone as the first approved medication for FSGS.

Strong Financial Performance

The company generated net product sales of $75.9 million in the first quarter, representing 90% growth over the same period last year.

Travere Therapeutics (TVTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TVTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.27 / -	-0.7	―	―	―
Aug 06, 2025	2025 (Q2)	-0.31 / -0.14	-0.91	84.62% (+0.77)	―
May 01, 2025	2025 (Q1)	-0.57 / -0.47	-1.76	73.30% (+1.29)	―
Feb 20, 2025	2024 (Q4)	-0.56 / -0.73	-1.18	38.14% (+0.45)	―
Oct 31, 2024	2024 (Q3)	-0.67 / -0.70	1.97	-135.53% (-2.67)	―
Aug 01, 2024	2024 (Q2)	-0.79 / -0.91	-1.13	19.47% (+0.22)	―
May 06, 2024	2024 (Q1)	-0.96 / -1.76	-1.27	-38.58% (-0.49)	―
Feb 15, 2024	2023 (Q4)	-1.16 / -1.18	-1.03	-14.56% (-0.15)	―
Nov 07, 2023	2023 (Q3)	-1.06 / 1.97	-1.09	280.73% (+3.06)	―
Aug 03, 2023	2023 (Q2)	-1.09 / -1.13	-1.05	-7.62% (-0.08)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TVTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$20.76	$21.15	+1.88%
Feb 20, 2025	$23.58	$21.98	-6.79%
Oct 31, 2024	$17.76	$17.50	-1.46%
Aug 01, 2024	$9.24	$9.00	-2.60%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Travere Therapeutics, Inc. (TVTX) report earnings?

Travere Therapeutics, Inc. (TVTX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Travere Therapeutics, Inc. (TVTX) earnings time?

Travere Therapeutics, Inc. (TVTX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TVTX EPS forecast?

TVTX EPS forecast for the fiscal quarter 2025 (Q3) is -0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing